Stem cells from a person's own fat compared with hyaluronic acid for knee osteoarthritis
Compares stem cell injections with hyaluronic acid injections in people with knee osteoarthritis.
Key facts
- Who runs it
- Yonsei University
- Where
- Incheon and Seoul, South KoreaSee the 3 sites
- Trial code
- Registry title
- Autologous Adipose-Derived Stem Cell Injections for Knee Osteoarthritis
- Status
- Recruiting
- People taking part
- 165 people, planned
- Started
- 3 Sept 2026
- Expected to end
- 31 May 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Autologous Adipose-Derived Mesenchymal Stem Cells (ADMSCs)
- Cross-linked Hyaluronic Acid (Synovian)
- Record updated
- 28 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with knee osteoarthritis and knee pain. It compares stem cells taken from their own belly fat with a hyaluronic acid injection into the knee.
- Age
- 40 to 70 years
- Sex
- All sexes
- Disease stage
- Knee osteoarthritis diagnosed by ACR criteria, with knee pain for at least 3 months. X-ray Kellgren-Lawrence grade II or III in the knee being studied. Pain during activity of at least 40 mm on a 100-mm pain scale. One or both knees may be affected.
- Earlier treatment
- Cannot join after a total or partial knee replacement in the studied knee. An earlier HTO bone surgery or partial meniscus removal at least 6 months ago, with a stable knee, is allowed. No cross-linked HA, cell therapy or gene therapy in the knee within 6 months. No linear HA or steroid injection in the knee within 3 months. No oral NSAIDs, glucosamine, chondroitin or oral steroids within 14 days before the injection.
Main reasons for not taking part
- Knee osteoarthritis caused by infection, rheumatoid arthritis or other inflammatory joint disease
- Body Mass Index (BMI) >= 35 kg/m2
- Uncontrolled diabetes (HbA1c > 8.5% (69 mmol/mol)) or a positive HIV antibody test
- Cancer within the last 3 years
- Pregnant or breastfeeding women
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Adults aged 40 to 70 years at the time of written informed consent
- Knee osteoarthritis diagnosed according to American College of Rheumatology (ACR) criteria with persistent knee pain for at least 3 months
- Radiographic Kellgren-Lawrence (KL) grade II or grade III in the target knee
- Activity pain score of >= 40 mm on a 100-mm Visual Analog Scale (VAS) in the target knee
- Unilateral or bilateral knee OA. In bilateral cases, one target knee must be designated according to criteria 1-4 (if both knees meet criteria, the more painful/symptomatic knee is selected)
- Voluntary provision of written informed consent
Who cannot take part
- Pain caused by meniscus posterior horn root tear within 3 months prior to screening
- Prior total knee arthroplasty (TKA) or unicompartmental knee arthroplasty (UKA) in the target knee (prior HTO or partial meniscectomy >= 6 months with stable status is permitted)
- Recent target knee treatments: cross-linked HA, cell therapy, or gene therapy within 6 months; linear HA or intra-articular corticosteroid within 3 months; oral NSAIDs, glucosamine, chondroitin, or oral steroids within 14 days prior to injection
- Participation in another clinical trial within 60 days prior to screening
- Secondary knee osteoarthritis caused by infection, rheumatoid arthritis, or inflammatory joint disease
- Pain judged to be caused by subchondral insufficiency fracture or osteonecrosis
- Conditions affecting joint pain or prognosis (e.g., gout, pseudogout, periarticular fracture, hemochromatosis, Wilson's disease, hypermobility, collagen gene disorders)
- Positive test for Human Immunodeficiency Virus (HIV) antibody
- History of malignant neoplasm within 3 years prior to screening
- Psychiatric disorder, alcohol/drug abuse affecting adherence or safety
- Uncontrolled type 1 or type 2 diabetes (HbA1c > 8.5% at screening)
- Clinically significant abnormal screening laboratory findings
- Body Mass Index (BMI) >= 35 kg/m2
- Pregnant or breastfeeding women
- Women of childbearing potential or men unwilling to use medically acceptable contraception during the trial
- Judged ineligible by the investigator
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 70 years old?
Where in South Korea
- Inha University HospitalIncheon, South KoreaContact: Dong-Jin Ryu, ProfessorTaking people
- Seoul National University HospitalSeoul, South KoreaContact: Byung-Sun Choi, ProfessorTaking people
- Severance hospitalSeoul, South KoreaContact: Sung-Hwan Kim, M.D., Ph.D.Taking people
About the trial
What the trial wants to find out
This multicenter, prospective, randomized, active-controlled, single-blind (assessor-blinded) clinical trial aims to evaluate the efficacy and safety of intra-articular injection of autologous adipose-derived mesenchymal stem cells (ADMSCs) compared with active comparator hyaluronic acid (HA) in patients with Kellgren-Lawrence grade II to III knee osteoarthritis. A total of 165 participants across 3 centers (Severance Hospital, Seoul National University Hospital, Inha University Hospital) will be randomly allocated to either the ADMSC group (1.0 x 10\^8 cells, single injection) or the HA group (Synovian, 3 mL) in a 2:1 ratio and followed for 6 months post-injection.
The 2 groups in the trial
- Autologous ADMSC InjectionTreatment being tested
Arm Description: Participants receive a single ultrasound-guided intra-articular injection of autologous adipose-derived mesenchymal stem cells (1.0 x 10\^8 cells/3 mL CryoStor 10) isolated and culture-expanded from the participant's abdominal subcutaneous adipose tissue.
Treatment: Autologous Adipose-Derived Mesenchymal Stem Cells (ADMSCs)
- Hyaluronic Acid InjectionExisting treatment, for comparison
Participants undergo identical abdominal liposuction and receive a single ultrasound-guided intra-articular injection of high-molecular-weight cross-linked hyaluronic acid (Synovian 3 mL). At the completion of the 6-month study period, cross-over autologous ADMSC injection is provided.
Treatment: Cross-linked Hyaluronic Acid (Synovian)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of Intra-articular Autologous Adipose-Derived Mesenchymal Stem Cell Injections for Improving Clinical Function in Patients With Knee Osteoarthritis: A Multicenter, Prospective, Randomized, Active-Controlled Trial
- Plain-language title
- Stem cells from a person's own fat compared with hyaluronic acid for knee osteoarthritisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Criteria questions
- Built from NCT07901790, who can take part
- Record updated
- 28 October 2026